Advances in Colorectal Cancer Screening-Ronald Schoengold-01/07/2014 - 8:30am

Event Information
Event Topic: 
Advances in Colorectal Cancer Screening
Event Date: 
01/07/2014 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA
Speaker Information
Event Speaker: 
Ronald Schoengold
Event Speaker Title: 
Event Speaker Company: 
E Gold Solutions Consulting
Event Speaker Bio: 

Ronald Schoengold

Ronald Schoengold has been an active contributor to the medical device, pharmaceutical and biomedical environment for over 45 years. His undergraduate studies were at St. John’s University (New York) and his graduate studies at Villanova University and Bryn Mawr College(PA). As a consultant to both large and small companies, he offers expert advice on quality systems, regulatory submissions and resolution of regulatory and quality problems. Ron is certified in regulatory affairs and has a proven record of accomplishment for integrating quality and regulatory requirements with technical, organizational and business development needs. He offers critical advice on the effective commercialization, support and maintenance of medical products and services and is an advisor to the National Institutes of Health, Commercialization Assistance Program, assisting companies awarded SBIR grants. Colorectal cancer screening has been a major focus of Ron’s professional pursuits. He has specialized training and hands-on experience in the development of screening and diagnostic tests in gastroenterology, notably the Hemoccult® fecal occult blood product lines, including guaiac and immunochemical based tests.

Event Details
Event Details: 

Colorectal cancer (CRC) is the second leading cause of cancer related deaths among both men and women in the United States. CRC is often referred to as the “silent” cancer because symptoms do not usually occur until later stages of the disease. Each year approximately 150,000 people are newly diagnosed and 50,000 die. Americans have a 5% lifetime risk for colorectal cancer. The incidence of CRC has been declining in the United States by 2% to 3% per year over the past 15 years. The most probable explanation for this trend is the increased awareness of the disease, especially among older individuals, and greater acceptance of screening among asymptomatic individuals. Despite this favorable trend, however, CRC screening in the U.S. is still underused with only about 2/3 of individuals who would benefit, accepting screening. Mortality and morbidity from CRC can be reduced significantly if polyps or adenomas are detected and removed, and if cancers are detected in early stages when they are most treatable. This talk will focus on advances in screening methods to detect adenomas and cancers. CRC is a preventable disease!